Table S6 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer

Key Points

Vγ9Vδ2 T cells show an antitumor profile linked to anti-PD-(L)1 responses, indicating a therapeutic avenue within triple-negative breast cancer.
Mass cytometry analysis demonstrates specific activation defects in Vγ9Vδ2 T cells, which are restored through anti-BTN3A treatment.
The study highlights the potential for using anti-BTN3A therapy to enhance Vγ9Vδ2 T cell activity against tumor cells in breast cancer.
Cancer treatments focusing on T cell responses, particularly those involving PD-L1 and BTN3A, may provide new strategies for managing triple-negative breast cancer.

We only have this paper's title and publication details.

Mass cytometry reveals Vγ9Vδ2 T cells exhibit antitumor profiles in triple-negative breast cancer, suggesting potential for anti-BTN3A therapy.

Mass cytometry panels, related to Figures 2 and 3

No takes yet. Share an insight, caveat, or question.

Fattori et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share